SEC 13F Intelligence

Boxer Capital, LLC / TCE2

Boxer Capital, LLC’s Celldex Therapeutics Inc New Position

Does Boxer Capital, LLC own Celldex Therapeutics Inc New (TCE2)? Not currently — the last reported position was 1.00M shares worth $18M in Q4 2020; the fund’s latest 13F (Q4 2024) no longer reports it.

Position Value
$18M
Q4 2020
Shares
1.00M
% of Portfolio
+0.56%
Quarters Held
3
position exited

Position History TCE2

Reported value by quarter
Q2 ’20: $13MQ2 ’20Q3 ’20: $15MQ3 ’20Q4 ’20: $18MQ4 ’20filingsflow.com
QuarterSharesValue% of Portfolio
Q4 20201.00M$18M+0.56%
Q3 20201.00M$15M+0.51%
Q2 20201.00M$13M+0.57%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Boxer Capital, LLC’s full portfolio or all institutional holders of TCE2.